Biotech: Page 5

  • An illustration of two lungs on a scientific background colored orange.
    Image attribution tooltip
    Mohammed Haneefa Nizamudeen via Getty Images
    Image attribution tooltip

    Intellia, ReCode partner on genetic medicines for cystic fibrosis

    The partnership will use Intellia's "DNA writing” technology, and focus on people with the lung disease who have limited or no available treatments

    By • Feb. 15, 2024
  • Image of business people walking past building with Wall Street sign.
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Aurinia to cut research after sale process fails to find a buyer

    The lupus drug developer said it engaged more than 60 parties during its eight-month business review, but only one expressed interest before walking away.

    By Kristin Jensen • Feb. 15, 2024
  • Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Explore the Trendline➔
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    COVID-19 vaccines

    The urgency of the pandemic’s first two years is giving way to questions of how to sustain public health responses and prepare for what could come next. In the U.S., health officials are urging booster shots and preparing for private sector distribution of vaccines.

    By BioPharma Dive staff
  • A firefly alights on a single plant stalk at dust.
    Image attribution tooltip
    Jeremy Hogan via Getty Images
    Image attribution tooltip
    Emerging biotech

    Versant-backed Firefly Bio wants to make the next generation of ADCs

    Armed with $94 million in funding, the biotech is marrying antibody-drug conjugates with protein degraders to create a new kind of cancer medicine.

    By • Feb. 15, 2024
  • A hospital bracelet is attached to a newborn infant's wrist.
    Image attribution tooltip
    Nenov via Getty Images
    Image attribution tooltip

    Sage offers details on launch of new postpartum depression pill

    The company and partner Biogen say signs from payers and doctors suggest the launch of Zurzuvae, the first oral therapy for PPD, is off to a good start.

    By Kristin Jensen • Feb. 14, 2024
  • A financial graph on an abstract background
    Image attribution tooltip
    monsitj via Getty Images
    Image attribution tooltip

    LianBio to shut down, return cash to investors

    The biotech is planning to dissolve less than four years after launching with plans to license drugs and market them in China and other Asian countries.

    By • Feb. 14, 2024
  • A 3D illustration of a nerve cell on a black background
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip
    Emerging biotech

    Hunting a non-opioid painkiller, a biotech reveals plans to chase Vertex

    Latigo Biotherapeutics has raised $135 million to develop drugs that block NaV1.8, the target of a Vertex therapy that just succeeded in Phase 3 trials.

    By • Feb. 14, 2024
  • Blue double exposure of money coins stacking with bar graph for financial and investment business concept.
    Image attribution tooltip
    Dilok Klaisataporn
    Image attribution tooltip

    BioAge raises $170M to back Phase 2-ready obesity drug

    BioAge’s Series D will fund a study combining its medicine with Eli Lilly’s Zepbound, a strategy the company hopes could help people lose weight while maintaining muscle mass.

    By • Feb. 13, 2024
  • A photo of a Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip
    New Alzheimer's drugs

    Biogen has a fuzzy line of sight on prized Alzheimer’s drug

    CEO Chris Viehbacher said there are about 3,800 U.S. patients on a registry for Leqembi. But Biogen doesn’t have all the details, as development partner Eisai is leading commercial efforts.

    By • Feb. 13, 2024
  • A 3D visualization of antibody drug conjugates.
    Image attribution tooltip
    Love Employee via Getty Images
    Image attribution tooltip

    ADC startup ProfoundBio, led by Seagen veterans, raises $112M

    The Series B round will fund development of antibody-drug conjugates now in clinical testing, among them a rival to AbbVie’s ovarian cancer drug Elahere.

    By • Feb. 13, 2024
  • Left: Anthony Philippakis, right: Krishna Yeshwant
    Image attribution tooltip
    Permission granted by GV
    Image attribution tooltip
    Q&A

    Two GV investors on biotech’s reset and building their next drug startups

    Newly named general partner Anthony Philippakis and managing partner Krishna Yeshwant discussed biotech’s newfound optimism and their investing “North Star.”

    By • Feb. 13, 2024
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Kalvista pill succeeds in late-stage study for rare swelling disorder

    The biotech's drug quickly alleviated symptoms of the swelling attacks associated with hereditary angioedema, supporting the idea it could be an oral alternative to existing medicines.

    By • Updated Feb. 13, 2024
  • A stock illustration of skin and fat tissue cells, viewed at cross section and colored pale pink.
    Image attribution tooltip
    Benjamin Toth via Getty Images
    Image attribution tooltip

    Alys launches with $100M and a pipeline of skin disease drugs

    European venture firm Medicxi built the startup by combining six of its portfolio companies, similar to when it merged 10 startups to form Centessa Pharmaceuticals in 2021.

    By • Feb. 12, 2024
  • A photo of Kyverna Therapeutics the day of its initial public offering on the Nasdaq stock exchange.
    Image attribution tooltip
    Permission granted by Kyverna Therapeutics
    Image attribution tooltip
    Q&A // Emerging biotech

    Kyverna CEO Peter Maag on courting investors in a ‘volatile’ IPO market

    After the CAR-T company priced one of the sector’s largest IPOs in recent years, Maag spoke with BioPharma Dive about what it takes to go public now.

    By • Feb. 9, 2024
  • A photo of the street sign for Wall Street, in front of a row of American flags.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip
    Emerging biotech

    Gene editing biotech Metagenomi pulls off nearly $94M IPO

    The company is one of just three preclinical biotechs to go public since last summer, but it raised significantly less than others that debuted with more advanced medicines.

    By • Feb. 8, 2024
  • Brain scans are seen in a stock image
    Image attribution tooltip
    sudok1 via Getty Images
    Image attribution tooltip

    Neurona raises another $120M for brain disease cell therapies

    The company’s haul is the latest sign brain drugs are recapturing the interest of investors after years of being passed over for other areas of research.

    By • Feb. 8, 2024
  • Image attribution tooltip
    Thomas Lohnes via Getty Images
    Image attribution tooltip

    BioNTech partners with Autolus to boost cell therapy manufacturing

    The German biotech will invest $200 million in Autolus — funds that, along with a $50 million fee, give it licensing options and access to supply infrastructure.

    By Kristin Jensen • Feb. 8, 2024
  • A photo of a nerve cell attacked by antibodies
    Image attribution tooltip
    peterschreiber.media via Getty Images
    Image attribution tooltip
    Emerging biotech

    Kyverna IPO adds to biotech momentum with $319M fundraise

    The company, a leading developer of cell therapies for autoimmune diseases, is the fifth drug startup to go public in 2024. All raised at least $100 million. 

    By • Feb. 7, 2024
  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip

    BridgeBio sells partial rights to dwarfism drug for $100M

    The deal hands Kyowa Kirin rights in Japan to the drug, which is emerging as a potential rival to BioMarin’s marketed medicine Voxzogo.

    By • Feb. 7, 2024
  • Left to right, headshots of Sam Hall, Aaron Kantoff and Tadd Wessel.
    Image attribution tooltip
    Permission granted by Scion Life Sciences
    Image attribution tooltip
    Emerging biotech

    Venture firm Scion Life Sciences launches with $310M to back new biotechs

    The new firm intends to carefully select its startups and fund them for the long haul. “We're not a company formation factory,” said co-founder Aaron Kantoff.

    By • Feb. 7, 2024
  • A portrait of Alex Morgan, partner at Khosla Ventures.
    Image attribution tooltip
    Permission granted by Khosla Ventures
    Image attribution tooltip
    Q&A // Emerging biotech

    Khosla Ventures’ Alex Morgan on biotech’s challenges and solving drug delivery

    The life sciences investor has backed a number of startups working on technologies for delivering and manufacturing cell and gene medicines.

    By • Feb. 6, 2024
  • Image attribution tooltip
    Flickr; Joel Penner
    Image attribution tooltip

    Valneva sells regulatory ‘fast pass’ for $103M

    The company said it will invest the sale proceeds into testing of an experimental Lyme disease shot and of Ixchiq, its new chikungunya vaccine.

    By • Feb. 5, 2024
  • A candlestick stock chart is seen out of focus against a background of $100 dollar bills in this composite stock image.
    Image attribution tooltip
    Honglouwawa via Getty Images
    Image attribution tooltip
    Emerging biotech

    Arch, a prolific biotech creator, is raising $3B for startup investing

    A regulatory filing shows the firm is putting together a new multibillion-dollar fund, roughly two years after raising a similar amount.

    By • Feb. 2, 2024
  • Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Brain drug developer Alto Neuroscience prices $129M IPO

    The biotech was joined by Fractyl Health in pricing an IPO Thursday evening, adding to last month’s stock offerings from CG Oncology and Arrivent BioPharma.

    By • Feb. 2, 2024
  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Avrobio’s road ends in reverse merger with Tim Springer-backed startup

    The gene therapy developer’s demise has given Tectonic Therapeutic, a GPCR-focused startup founded by the prolific biotech entrepreneur, an alternate path to the public markets.

    By Kristin Jensen • Jan. 31, 2024
  • An illustration of antibodies attacking a nerve cell.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Cour gets $105M, pharma help to ‘reprogram’ autoimmune disease

    Roche, Pfizer and Bristol Myers Squibb have all invested in the startup, which is using nanoparticle technology to retrain the body’s immune system.

    By • Jan. 30, 2024